Annual report
2784.TEDINET S100OHEM
Period2021-04-01 → 2022-03-31
Filed2022-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.59T | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥2.61T | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Revenue | ¥2.70T | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.64T | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.60T | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥29.1bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Operating income | ¥27.9bn | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Ordinary income | ¥32.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥31.9bn | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥57.2bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥55.1bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥51.9bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥48.2bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥36.5bn | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥32.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥24.5bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥40.3bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥41.7bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥35.6bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥32.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Net income | ¥24.5bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Total assets | ¥1.30T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.32T | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥1.35T | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.34T | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.34T | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥832.2bn | at 2022-03-31 | Cons. | Liabilities |
| Total liabilities | ¥826.7bn | at 2021-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥471.8bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥490.0bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥474.9bn | at 2020-03-31d | Cons. | Net assets |
| Net assets / equity | ¥442.1bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥435.9bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥180.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥170.3bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥179.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥169.1bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥209.3bn | at 2020-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥205.1bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥195.6bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥36.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥21.2bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥33.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥46.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥47.6bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥2.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.7bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥17.0bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥12.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥10.2bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥29.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥14.5bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥12.6bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥24.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥9.9bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥153.57 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥115.75 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥190.26 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥195.91 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥164.25 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,330.36 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,313.66 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,237.89 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,083.03 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,006.53 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 36.2% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.2% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.0% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.9% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.5% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 6.7% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.1% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.8% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.5% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.6% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 11,925 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 12,045 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 12,074 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 12,076 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 11,901 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥17.2bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥25.3bn | 2020-04-01 → 2021-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥26.1bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥22.0bn | 2018-04-01 → 2019-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥19.6bn | 2017-04-01 → 2018-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥15.2bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥23.4bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥15.4bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥23.7bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥24.5bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥20.2bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.0bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥13.7bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥24.1bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥13.6bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥23.9bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥22.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥20.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥17.9bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥265.3bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥277.5bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥260.4bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥248.3bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥252.8bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥17.7bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥16.2bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥247.6bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥261.3bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥248.3bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥236.1bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥239.5bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥21.0bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥33.0bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥64.88 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥112.78 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥105.2 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥94.74 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.64 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥54 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥53 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥39 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,223.58 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,234.61 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,173.2 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,115.63 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,105.38 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 93.3% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.2% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.4% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.1% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.7% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 5.3% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.6% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 235,017,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 44 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 38 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 38 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 38 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 42 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 84
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥2.1bn |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥2.1bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥29.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥29.1bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥15.5bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | ¥332m |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥9.6bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥6.0bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | employees | at 2022-03-31 | 8931 pure |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥2.29T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥2.27T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥15.7bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment assets | at 2022-03-31 | ¥1.12T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥24.8bn |
| Manufacturing Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥3.9bn |
| Manufacturing Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥3.3bn |
| Manufacturing Businessreportable segment | employees | at 2022-03-31 | 1370 pure |
| Manufacturing Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥47.4bn |
| Manufacturing Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥34.6bn |
| Manufacturing Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥12.8bn |
| Manufacturing Businessreportable segment | segment assets | at 2022-03-31 | ¥70.5bn |
| Manufacturing Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.9bn |
| Medical Related Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥426m |
| Medical Related Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥387m |
| Medical Related Businessreportable segment | employees | at 2022-03-31 | 1108 pure |
| Medical Related Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥34.5bn |
| Medical Related Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥34.5bn |
| Medical Related Businessreportable segment | segment assets | at 2022-03-31 | ¥16.7bn |
| Medical Related Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥183m |
| Self Medication Products Wholesaling Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥306m |
| Self Medication Products Wholesaling Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥357m |
| Self Medication Products Wholesaling Businessreportable segment | employees | at 2022-03-31 | 400 pure |
| Self Medication Products Wholesaling Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥244.8bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥244.2bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥610m |
| Self Medication Products Wholesaling Businessreportable segment | segment assets | at 2022-03-31 | ¥83.0bn |
| Self Medication Products Wholesaling Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥14.2bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥10.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥2.61T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥2.59T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥29.1bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥1.29T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥28.8bn |
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | ¥2.1bn |
| Reconciling Itemsreconciling | depreciation | 2020-04-01 → 2021-03-31 | ¥2.3bn |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥25.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥25.1bn |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥34.4bn |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | ¥332m |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥22.9bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥5.1bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥2.30T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥2.28T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥15.2bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment assets | at 2021-03-31 | ¥1.11T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥25.6bn |
| Manufacturing Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥3.6bn |
| Manufacturing Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥3.1bn |
| Manufacturing Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥42.6bn |
| Manufacturing Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥33.2bn |
| Manufacturing Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥9.4bn |
| Manufacturing Businessreportable segment | segment assets | at 2021-03-31 | ¥65.6bn |
| Manufacturing Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | −¥144m |
| Medical Related Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥673m |
| Medical Related Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥355m |
| Medical Related Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥33.3bn |
| Medical Related Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥33.3bn |
| Medical Related Businessreportable segment | segment assets | at 2021-03-31 | ¥17.5bn |
| Medical Related Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | −¥360m |
| Self Medication Products Wholesaling Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥280m |
| Self Medication Products Wholesaling Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥410m |
| Self Medication Products Wholesaling Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥261.7bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥261.2bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥527m |
| Self Medication Products Wholesaling Businessreportable segment | segment assets | at 2021-03-31 | ¥88.0bn |
| Self Medication Products Wholesaling Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥2.5bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2020-04-01 → 2021-03-31 | ¥27.4bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2020-04-01 → 2021-03-31 | ¥8.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2020-04-01 → 2021-03-31 | ¥2.64T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2020-04-01 → 2021-03-31 | ¥2.61T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥25.1bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2021-03-31 | ¥1.28T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2020-04-01 → 2021-03-31 | ¥27.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,156
| Item | Context | Value | Unit |
|---|---|---|---|
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row39Member | Original text (Japanese)・同業界内における関係維持発展に伴う中 長期的な企業価値の向上・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row39Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row40Member | Original text (Japanese)㈱メディパルホールディングス | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row40Member | Original text (Japanese)・同業界内における関係維持発展に伴う中 長期的な企業価値の向上・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row40Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row41Member | Original text (Japanese)東邦ホールディングス㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row41Member | Original text (Japanese)・同業界内における関係維持発展に伴う中 長期的な企業価値の向上・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row41Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row42Member | Original text (Japanese)㈱ヤクルト本社 | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row42Member | Original text (Japanese)・良好な取引関係の維持発展・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row42Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row43Member | Original text (Japanese)大日本住友製薬㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row43Member | Original text (Japanese)・良好な取引関係の維持発展・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row43Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row44Member | Original text (Japanese)日本新薬㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row44Member | Original text (Japanese)・良好な取引関係の維持発展・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row44Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row45Member | Original text (Japanese)㈱三菱ケミカルホールディングス | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row45Member | Original text (Japanese)・良好な取引関係の維持発展・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row45Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row46Member | Original text (Japanese)参天製薬㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row46Member | Original text (Japanese)・良好な取引関係の維持発展・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row46Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row47Member | Original text (Japanese)シスメックス㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row47Member | Original text (Japanese)・良好な取引関係の維持発展・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row47Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row48Member | Original text (Japanese)㈱ココカラファイン | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row48Member | Original text (Japanese)・良好な取引関係の維持発展・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row48Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row49Member | Original text (Japanese)旭化成㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row49Member | Original text (Japanese)・良好な取引関係の維持発展・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row49Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row50Member | Original text (Japanese)鳥居薬品㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row50Member | Original text (Japanese)・良好な取引関係の維持発展・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row50Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row51Member | Original text (Japanese)協和キリン㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row51Member | Original text (Japanese)・良好な取引関係の維持発展・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row51Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row52Member | ㈱ＪＭＳ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row52Member | Original text (Japanese)・良好な取引関係の維持発展・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row52Member | Original text (Japanese)無 | |
| Name of group company holding second largest amount of investment shares in group | CurrentYearInstant | Original text (Japanese)明祥株式会社 | |
| Reason for increase in number of shares shares not listed investment shares held for purposes other than pure investment second largest holding company | CurrentYearDuration | Original text (Japanese)取引先持株会会員 | |
| Reason for increase in number of shares shares other than those not listed investment shares held for purposes other than pure investment second largest holding company | CurrentYearDuration | Original text (Japanese)取引先持株会会員 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)大塚ホールディングス㈱ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)・良好な取引関係の維持発展・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)無(注)３ | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row2Member | Original text (Japanese)㈱クスリのアオキホールディングス | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row2Member | Original text (Japanese)・良好な取引関係の維持発展・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment second largest holding company | CurrentYearInstant_Row2Member | Original text (Japanese)無 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |